Featured Research

from universities, journals, and other organizations

Lung cancer: Drug with unique disruption of tumor blood flow shows promise

Date:
January 18, 2010
Source:
American Association for Cancer Research
Summary:
Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer.

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

Related Articles


Results of this study, which were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, support ongoing Phase III studies of ASA404 in NSCLC.

Under development by Novartis, who licensed the drug from Antisoma, ASA404 (vadimezan) has a unique mechanism of action against a tumor's blood supply. Scientists have long known that choking off this blood supply through a process called anti-angiogenesis is one way to slow tumor growth. Bevacizumab (sold as Avastin by Genentech) is one of many angiogenesis inhibitors and has had a major impact on patient care.

"Bevacizumab, however, predominantly interferes with the formation of new blood vessels," said lead researcher Mark McKeage, Ph.D., an associate professor in clinical pharmacology at the University of Auckland. "ASA404 has been shown to cause selective disruption of the established tumor vasculature, inhibition of tumor blood flow and tumor necrosis."

This unique mechanism of action could provide an option for patients with either squamous or non-squamous NSCLC. Treatment options for patients with advanced stage NSCLC are limited, particularly for those with squamous histology where some treatments exhibit limited efficacy or serious side effects.

"Standard chemotherapy is currently the mainstay of treatment for patients with squamous NSCLC. New targeted therapies and chemotherapies have been evaluated, but many show little promise as first-line treatments in patients with this type of cancer," said McKeage.

McKeage and colleagues evaluated 108 patients with stage IIIb/IV NSCLC. Patients received six cycles of paclitaxel and carboplatin alone or the therapy cycles with ASA404. The researchers then compared the results by histology (squamous vs. non-squamous) and by treatment (chemotherapy plus ASA404 vs. chemotherapy alone).

Overall survival was much higher in patients treated with ASA404. In patients with squamous histology, survival was 10.2 months compared with 5.5 months among those treated with chemotherapy alone. In patients with non-squamous histology, survival was 14.9 months compared with 11 months among those treated with chemotherapy alone.

The addition of ASA404 did not appear to increase toxicity, and there were no serious adverse events associated with bleeding, pulmonary hemorrhage or hemoptysis. Rates of grade 3 or 4 anemia were not different, nor were rates of thrombocytopenia or neutropenia.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Lung cancer: Drug with unique disruption of tumor blood flow shows promise." ScienceDaily. ScienceDaily, 18 January 2010. <www.sciencedaily.com/releases/2010/01/100112165110.htm>.
American Association for Cancer Research. (2010, January 18). Lung cancer: Drug with unique disruption of tumor blood flow shows promise. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2010/01/100112165110.htm
American Association for Cancer Research. "Lung cancer: Drug with unique disruption of tumor blood flow shows promise." ScienceDaily. www.sciencedaily.com/releases/2010/01/100112165110.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins